The ebmt activity survey report 2017: a focus on allogeneic hct for nonmalignant indications and on the use of non-hct cell therapies - Université de Lille Accéder directement au contenu
Article Dans Une Revue Bone Marrow Transplantation Année : 2019

The ebmt activity survey report 2017: a focus on allogeneic hct for nonmalignant indications and on the use of non-hct cell therapies

Jakob Passweg
  • Fonction : Auteur
Helen Baldomero
  • Fonction : Auteur
Grzegorz Wladyslaw Basak
  • Fonction : Auteur
Christian Chabannon
  • Fonction : Auteur
Selim Corbacioglu
  • Fonction : Auteur
Rafael F. Duarte
  • Fonction : Auteur
Jurgen Kuball
  • Fonction : Auteur
Arjan Lankester
  • Fonction : Auteur
Silvia Montoto
  • Fonction : Auteur
Regis Peffault de Latour
  • Fonction : Auteur
John A. Snowden
  • Fonction : Auteur
Jan Styczynski
  • Fonction : Auteur
Mutlu Arat
  • Fonction : Auteur
Mohamad Mohty
  • Fonction : Auteur
Nicolaus Kroger
  • Fonction : Auteur

Résumé

Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants done in Europe and associated countries continues to rise with 45,418 HCT in 41,100 patients [(17,155 allogeneic (42%) and 23,945 autologous (58%)] reported by 683 centers in 50 countries in 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid malignancies 26,488 (64%; 19% allogeneic), solid tumors 1,607 (3.9%; 2% allogeneic), and nonmalignant disorders 2,667 (7%; 81% allogeneic). Trends in donor choice seen before continue, with growing numbers of haploidentical HCT and decreasing use of cord blood. Of interest is that after many years of continued growth, the number of patients receiving an allogeneic HCT for marrow failure is decreasing slightly (p < 0.001). Such a change may be explained by the use of thrombopoietin analogs in aplastic anemia patients. Other nonmalignant indications, however continue to grow, most importantly HCT for hemoglobinopathies by 36%, equally for thalassemias and sickle cell disease. Non-HCT cell therapies have increased by 28% since 2015 and genetically modified T cells is type of cell therapy with the fastest growth. These annual reports reflect current activity and trends and are useful for health-care planning.
Fichier principal
Vignette du fichier
s41409-019-0465-9.pdf (1.79 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04428654 , version 1 (31-01-2024)

Identifiants

Citer

Jakob Passweg, Helen Baldomero, Grzegorz Wladyslaw Basak, Christian Chabannon, Selim Corbacioglu, et al.. The ebmt activity survey report 2017: a focus on allogeneic hct for nonmalignant indications and on the use of non-hct cell therapies. Bone Marrow Transplantation, 2019, Bone Marrow Transplantation, 54, pp.1575-1585. ⟨10.1038/s41409-019-0465-9⟩. ⟨hal-04428654⟩

Collections

RIIP UNIV-LILLE
5 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More